Regeneron Pharmaceuticals, Inc.

Joyce Harp

Haruka Okamoto

Mark Sleeman

Stephen R Jaspers

Jesper Gromada

Mark W Sleeman

The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis and long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels.

Human antibodies to the human glucagon receptor (HGCGR) and methods of use thereof to lower blood glucose or ketone levels

Provided herein are methods of treating a patient with severe insulin resistance. The methods comprise administering to a patient in need thereof a therapeutic amount of a GCG/GCGR signaling pathway inhibitor, such that blood glucose or beta-hydroxybutyrate levels are lowered or that the severe insulin resistance is mediated, or a condition or disease characterized by severe insulin resistance is mediated, or at least one symptom or complication associated with the condition or disease is alleviated or reduced in severity. The GCG/GCGR signaling pathway inhibitor can be a small molecule inhibitor of the signaling pathway, an antisense inhibitor of the signaling pathway, a GCG neutralizing monoclonal antibody, a GCGR antagonist, a peptide inhibitor of the signaling pathway, a DARPin, a Spiegelmer, an aptamer, engineered Fn type-III domains, etc. The therapeutic methods are useful for treating a human suffering from severe insulin resistance.

Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

Human antibodies to the human glucagon receptor and methods of use thereof to lower blood glucose or ketone levels

Nucleic acid molecules encoding antibodies to the human glucagon receptor

Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels

Human antibodies to the glucagon receptor and methods of use thereof

The present invention provides antibodies that bind to the human glucagon receptor, designated GCGR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human GCGR. The antibodies of the invention are useful for lowering blood glucose levels and blood ketone levels and are also useful for the treatment of diseases and disorders associated with one or more GCGR biological activities, including the treatment of diabetes, diabetic ketoacidosis, long-term complications associated with diabetes, or other metabolic disorders characterized in part by elevated blood glucose levels, including stress hyperglycemia.

Method of treating stress hyperglycemia with human antibodies to the glucagon receptor

Nucleic acids encoding human glucagon receptor antibodies

Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor

Human antibodies to the human glucagon receptor and methods of use thereof

Growing community of inventors

White Plains, NY, United States of America

Joyce Harp